Dermagnostix closes Seed Plus Funding Round of €4.6 M

Molecular diagnostics of skin diseases

25-Aug-2022 - Dermagnostix has closed a €4.6 M Seed Plus to launch its revolutionary microfluidics-based system for diagnostics of skin diseases. Over the past months the outstanding team has developed the first product PsorX for the upcoming market entry and complemented the team with highly motivated ...

Medix Biochemica acquires myPOLS Biotec

All founders of myPOLS Biotec will remain involved in the business following the acquisition

07-Feb-2022 - Medix Biochemica has acquired 100 percent of the shares of myPOLS Biotec GmbH. As a result of the acquisition, Medix Biochemica broadens its portfolio of molecular diagnostic raw materials for the in vitro diagnostics (“IVD”) industry, complements its scientific expertise and strengthens its ...

Startup revolutionizes diagnostics in dermatology

Dermagnostix closes seven-figure seed round

17-Dec-2021 - Dermagnostix revolutionizes diagnostics in dermatology with its fully auto-mated "lab-in-a-box" system, which allows the technically valid performance of complex molecular assays. "Modern molecular diagnostics is a prerequisite for implementing precision medicine in dermatology. It not only ...

QIAGEN fully acquires NeuMoDx Molecular

QIAGEN acquires remaining 80.1% stake in NeuMoDx Molecular, Inc. for $248 million

18-Sep-2020 - QIAGEN N.V. announced the acquisition of the remaining 80.1% of diagnostics instruments company NeuMoDx Molecular, Inc. for $248million in cash. The move rounds out QIAGEN’s portfolio of automated molecular testing solutions based on the proven PCR technology. The transaction was completed after ...

Molzym is Part of Gradian Diagnostics

11-Feb-2020 - Gradian Diagnostics announced that Molzym GmbH & Co. KG is joining Gradian Diagnostics. Molzym will become the first acquisition, bringing a wide set of products and services due to their wealth of experience and expertise in molecular microbial analysis, and their focus on deep research and ...

QIAGEN acquires Spanish diagnostics start-up company

QIAGEN enters into agreement to acquire STAT-Dx

09-Feb-2018 - QIAGEN N.V. announced it has entered into an agreement to acquire STAT-Dx, a privately-held company developing the next generation of multiplex diagnostics for one-step, fully integrated molecular analysis of common syndromes using a novel system based on real-time PCR technology and proven ...

Hummingbird Diagnostics and Saarland University Collaborate in Early Disease Detection Based on Molecular Markers

16-Nov-2017 - Hummingbird Diagnostics GmbH, specialized in early disease detection using molecular markers derived from blood, and Saarland University agreed on a comprehensive framework agreement regarding an expanded collaboration in the field of molecular diagnostics. The work aims at the validation of ...

Agilent Technologies and Burning Rock sign agreement on molecular diagnostics

30-Sep-2016 - Agilent Technologies Inc. and Burning Rock today announced they have signed an agreement under which Burning Rock will develop cancer diagnostics in China based on the Agilent SureSelect target enrichment system. Agilent is the leading provider of target enrichment for next-generation DNA ...

Siemens acquires NEO New Oncology AG

Siemens Healthcare GmbH enters field of molecular services for oncology

20-May-2016 - Siemens Healthineers has expanded its diagnostics portfolio with the acquisition of NEO New Oncology AG, Cologne, Germany. The company's cancer genome diagnostic platform NEO will support pathologists and oncologists with comprehensive molecular information to help select targeted cancer ...

Merck and Biocartis to Collaborate

08-Jan-2016 - Merck announced that it has signed a collaboration agreement with Biocartis for the development and commercialization of a new liquid biopsy RAS biomarker test for patients with metastatic colorectal cancer (mCRC). The test will be developed on Biocartis’ innovative, fully automated molecular ...